Remission in pediatric inflammatory bowel disease correlates with prescription refill adherence rates

Journal of Pediatric Gastroenterology and Nutrition

Volumn 64, Issue 4, 2017, Pages 575-579

  Samson, Charles M ^a   Mager, Douglas ^b   Frazee, Sharon ^b   Yu, Feliciano ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

5 aminosalicylic acid; adalimumab; Crohn; pharmacy benefit management; thiopurine; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PRESCRIPTION DRUG; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; CLINICAL OUTCOME; CONFERENCE PAPER; CROHN DISEASE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; MONOTHERAPY; OUTPATIENT; PATIENT COMPLIANCE; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; CHILD; COMBINATION DRUG THERAPY; INDUCTION CHEMOTHERAPY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84974686411     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001304     Document Type: Conference Paper

References (34)

1. Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol 2004;99:650-5.
2. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohns disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13.
3. Sabate E. Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: World Health Organization; 2003.
4. Lemanek K. Adherence issues in the medical management of asthma. J Pediatr Psychol 1990;15:437-58.
5. Rapoff MA. Adherence to Pediatric Medical Regimens. New York: Kluwer Academic; 1999.
6. Sly RM. Mortality from asthma in children 1979-1984. Ann Allergy 1988;60:433-43.
7. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and costs of ulcerative colitis flares. Aliment Pharmacol Ther 2009;29:247-57.
8. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53:1020-4.
9. Gillespie D, Hood K, Farewell D, et al. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflamm Bowel Dis 2014;20:82-91.
10. Robinson A, Hankins M,Wiseman G, et al. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther 2013;38:531-8.
11. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcome of patients with quiescent ulcerative colitis. Am J Med 2003;114:39-43.
12. Kawakami A, Tanaka M, Nishigaki M, et al. Relationship between nonadherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 2013;48:1006-15.
13. Hommel KA, Mackner LM, Denson LA, et al. Treatment regimen adherence in pediatric gastroenterology. J Pediatr Gastroenterol Nutr 2008;47:526-43.
14. Charland SL, Agatep BC, Herrera V, et al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the additional KIF6 risk offers better adherence to statins (AKROBATS) trial. Pharmacogenomics J 2014;14:272-80.
15. Kane SV, Sumner M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci 2011;56:3463-70.
16. Kappelman MD, Crandall WV, Colletti RB, et al. Short Pediatric Crohns Disease Activity Index for quality improvement and observational research. Inflamm Bowel Dis 2011;17:112-7.
17. Turner D, Otley AR, Mack D, et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 2007;133:433-42.
18. Samson CM, Morgan P, Williams E, et al. Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease. J Pediatr Gastro Enterol Nutr 2012;55:679-88.
19. Andrade SE, Kahler KH, French F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74.
20. Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009;15:589-93.
21. Iglay K, Cao X, Mavros P, et al. Systematic literature review and metaanalysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther 2015;37:1813-21.
22. Visaria J, Frazee SG. Role of pharmacy channel in adherence to hepatitis C regimens. Am J Pharm Benefits 2013;5:17-24.
23. Iyengar R, Henderson R, Visaria J, et al. Dispensing channel and medication adherence: evidence across 3 therapy classes. Am J Manag Care 2013;19:798-804.
24. Crandall WV, Margolis PA, Kappelman MD, et al. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics 2012;129:e1030-41.
25. Greenly RN, Kunz JH, Biank V, et al. Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:1254-9.
26. Trindade AJ, Ehrlich A, Kornbluth A, et al. Are your patients taking their medication? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011;17:599-604.
27. Moss AC, Lillis Y, Edwards George JB, et al. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol 2014;109:1850-5.
28. Rohan JM, Drotar D, Alderfer M, et al. Electronic monitoring of medication adherence in early maintenance phase of treatment for pediatric leukemia and lymphoma: identifying patterns of nonadherence. J Pediatr Psychol 2015;40:75-84.
29. LeLeiko NS, Lobato D, Hagin S, et al. Rates and predictors of oral medication adherence in pediatric patients with IBD. Inflamm Bowel Dis 2013;19:832-9.
30. Kamperidis N, Goodhand JR, Chowdhury FA, et al. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastro Enterol Nutr 2012; 54:685-9.
31. Goodhand JR, Kamperidis N, Sirwan B, et al. Factors associated with thiopurine nonadherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:1097-108.
32. Greenley RN, Karazsia B, Schurman JV, et al. Trajectories of oral medication adherence in youth with inflammatory bowel disease. Health Psychol 2015;34:514-21.
33. Mackner LM, Crandall WC. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005;11:1006-12.
34. Oliva-Hemker MM, Abadom V, Cuffari C, et al. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohns disease. J Pediatr Gastroenterol Nutr 2007; 44:180-4.